<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01697423</url>
  </required_header>
  <id_info>
    <org_study_id>2012-003565-18</org_study_id>
    <secondary_id>2011-25</secondary_id>
    <nct_id>NCT01697423</nct_id>
  </id_info>
  <brief_title>Comparative Assessment of Intra-articular Knee Injections of Platelet-rich Plasma (PRP) and Hyaluronic Acid in the Treatment of Knee Osteoarthritis</brief_title>
  <official_title>Comparative Assessment of Intra-articular Knee Injections of Platelet-rich Plasma (PRP) and Hyaluronic Acid in the Treatment of Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of cartilage pathology has grown due to the ageing population, and the increase&#xD;
      in sports participation and its associated trauma. The aim of the treatment of symptomatic&#xD;
      osteoarthritis consists in reducing pain and improving the knee function in order to limit&#xD;
      the sport, professional and social negative impact in the youngest patients.&#xD;
&#xD;
      The symptomatic treatment of knee osteoarthritis associates painkillers and non steroid anti&#xD;
      inflammatory drugs (nsad). In case of ineffectiveness of the oral drugs intra articular&#xD;
      injections are proposed.&#xD;
&#xD;
      Intra articular injections of hyaluronic acid are recommended by the American College of&#xD;
      Rheumatology and the European League against Rheumatism for the treatment of knee&#xD;
      osteoarthritis. Nevertheless their efficacy remain non predictable in patients so as the&#xD;
      duration of clinical improvement which does not exceed 6 months.&#xD;
&#xD;
      The articular cartilage has a limited capacity for self-repair due to the low mitotic&#xD;
      activity of chondrocytes and its avascularity.&#xD;
&#xD;
      Platelet-rich plasma is a natural concentrate of growth factors: PDGF, TGF b, IGF-1, FGF and&#xD;
      the cytokines, liberated by platelet degranulation. The influence of these growth factors in&#xD;
      the cartilage repair is being widely investigated in vivo and in vitro. These factors could&#xD;
      stimulate the chondral reparation via a neovascularization, a collagen synthesis and an&#xD;
      activation of the chondrocytes.&#xD;
&#xD;
      The hypothesis is that the intra articular injection of PRP, with its capacity to enhance&#xD;
      articular cartilage repair, could be a therapeutic alternative to hyaluronic acid in the&#xD;
      treatment of knee osteoarthritis resisting the oral drugs.&#xD;
&#xD;
      Material and methods: We intend to conduct a comparative, monocentric prospective randomized,&#xD;
      double-blind study on 80 patients with symptomatic knee osteoarthritis to compare the results&#xD;
      of 2 intra articular treatment: platelet-rich plasma and hyaluronic acid.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of the functional score of WOMAC</measure>
    <time_frame>12 months</time_frame>
    <description>evaluate the non inferiority between platelet-rich plasma (PRP) and hyaluronic acid. onthé evolution of the knee function, by assessing the difference with a functional score (WOMAC), before and 3 months after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the evolution of pain</measure>
    <time_frame>12month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>the Treatment of Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>platelet-rich plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>durolane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>platelet-rich plasma</intervention_name>
    <arm_group_label>platelet-rich plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>durolane</intervention_name>
    <arm_group_label>durolane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Males and females between 20 to 75 years of age 2. Symptomatic knee arthritis 3.&#xD;
             Axial deformity of the lower limb equal or lower than 5° 4. BMI between 20 to 30 5.&#xD;
             Written informed consent, signed by patient or legal representative (if patient unable&#xD;
             to sign).&#xD;
&#xD;
             6. HB &gt; 10g/dl 7. Negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Axial deformity of the lower limb over 5°&#xD;
&#xD;
          2. Knee instability&#xD;
&#xD;
          3. BMI &lt; 20 or &gt; 30&#xD;
&#xD;
          4. Thrombocytopenia &lt; 150 G/L&#xD;
&#xD;
          5. Thrombopathy&#xD;
&#xD;
          6. Anaemia: HB &lt; 10g/dl&#xD;
&#xD;
          7. Positive serology VIH1 and 2, Agp24, Ac HCV, Ag HbS, AcHbc, Ac HTLV I and II, TPHA&#xD;
&#xD;
          8. Chronic treatment by corticosteroid per os or treatment completed more than 2 weeks&#xD;
             before inclusion&#xD;
&#xD;
          9. Intra articular knee injection of corticosteroid or completed more than 8 weeks before&#xD;
             inclusion&#xD;
&#xD;
         10. Intra articular knee injection of hyaluronic or completed more than 24 weeks before&#xD;
             inclusion&#xD;
&#xD;
         11. NSAI treatment completed more than 2 weeks before inclusion&#xD;
&#xD;
         12. Fever or recent disease&#xD;
&#xD;
         13. Auto immune disease&#xD;
&#xD;
         14. Inflammatory Arthritis&#xD;
&#xD;
         15. Immune deficit&#xD;
&#xD;
         16. Infectious disease&#xD;
&#xD;
         17. Pregnancy&#xD;
&#xD;
         18. Patient under guardianship.&#xD;
&#xD;
         19. Participation in another investigational trial within this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BERNARD BELAIGUES</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>marie laure LOUIS</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP HM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>marie laure LOUIS</last_name>
    <email>marielaure.louis@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARIE LAURE LOUIS</last_name>
    </contact>
    <investigator>
      <last_name>MARIE LAURE LOUIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>September 28, 2012</study_first_submitted>
  <study_first_submitted_qc>September 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2012</study_first_posted>
  <last_update_submitted>November 9, 2015</last_update_submitted>
  <last_update_submitted_qc>November 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

